Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
IF:
1.3
5-Year IF:
2.6
Eigenfactor:
0.00079
JCI:
0.24
SJR:
0.429
SNIP:
0.287
CiteScore™::
2.7
H-Index:
81
Indexed in
Avelumab: A Novel Anti-PD-L1 Agent in the Treatment of Merkel Cell Carcinoma and Urothelial Cell Carcinoma
Get access
RESUMO
Long-term treatment in the setting of metastatic Merkel cell carcinoma (MCC) and urothelial carcinoma (UC) has shown that current first-line chemotherapeutic agents are losing effectiveness and that there are limited treatment options available outside of radiation therapy and surgical interventions. The use of immunotherapeutic agents such as monoclonal antibodies has been considered a promising alternative for cancers that progress despite treatment with radiation therapy, surgery, and/or chemotherapeutic agents. Cancer cells escape immune surveillance by interrupting immune checkpoint pathways, resulting in dysregulation of T-cell function and so preventing its antitumor effects. In early 2017, avelumab (BAVENCIO®), a PD-L1–blocking monoclonal antibody agent, was approved for the treatment of metastatic MCC and UC. Trials that evaluated avelumab for the treatment of metastatic MCC and UC were the JAVELIN Merkel 200 Trial and the JAVELIN Solid Tumor trial, respectively. Efficacy results for both trials showed positive overall response rate (ORR) and progression-free survival rate (PFS). A strong safety profile was also established for avelumab. This review provides a brief introduction to checkpoint inhibitors and focuses on the recently approved PD-L1 inhibitor, avelumab.
-
Barrueto Luisa, Caminero Francheska, Cash Lindsay, Makris Courtney, Lamichhane Purushottam, Deshmukh Rahul R., Resistance to Checkpoint Inhibition in Cancer Immunotherapy, Translational Oncology, 13, 3, 2020. Crossref
-
Barbari Cody, Fontaine Tyler, Parajuli Priyanka, Lamichhane Narottam, Jakubski Silvia, Lamichhane Purushottam, Deshmukh Rahul R., Immunotherapies and Combination Strategies for Immuno-Oncology, International Journal of Molecular Sciences, 21, 14, 2020. Crossref
-
Mortensen Michael J, Oatman Oliver, Azadi Amir, Fonkem Ekokobe, Yuen Kevin CJ, An Update on Immune Checkpoint Inhibitor-related Hypophysitis, US Endocrinology, 16, 2, 2020. Crossref
-
Zhukova N. V., Orlova R. V., Kaledina E. A., Naymushina P. A., Malkova A. M., Beliak N. P., Key differences between anti-PD-1/PD-L1 inhibitors, Meditsinskiy sovet = Medical Council, 9, 2022. Crossref
-
Orlova Rashida, Zhukova Natalia, Malkova Anna, Shoenfeld Yehuda, Hypothesis for the development of immune-related adverse events in immune checkpoint inhibitors therapy, Cancer Treatment and Research Communications, 31, 2022. Crossref
-
Maghrouni Abolfazl, Givari Maryam, Jalili-Nik Mohammad, Mollazadeh Hamid, Bibak Bahram, Sadeghi Mohammad Montazami, Afshari Amir R., Johnston Thomas P., Sahebkar Amirhossein, Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions, International Immunopharmacology, 93, 2021. Crossref